Emerging drug targets for achondroplasia

被引：2
|
作者：
Savarirayan, Ravi [1 ]
机构：
[1] Univ Melbourne, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia
来源：
EXPERT OPINION ON THERAPEUTIC TARGETS | 2022年 / 26卷 / 05期
关键词：
Skeletal dysplasia; therapeutics; clinical trials; achondroplasia; drug targets; FGFR3; mutation; fibroblast growth factor receptor 3; mouse models; GROWTH; MUTATIONS; DWARFISM; CHILDREN; THERAPY; CNP;
D O I：
10.1080/14728222.2022.2077722
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：389 / 391
页数：3
相关论文
共 50 条
  • [1] Emerging Drug Targets for Endometriosis
    Dolmans, Marie-Madeleine
    Donnez, Jacques
    BIOMOLECULES, 2022, 12 (11)
  • [2] Emerging drug targets for antiretroviral therapy
    Reeves, JD
    Piefier, AJ
    DRUGS, 2005, 65 (13) : 1747 - 1766
  • [3] Emerging Drug Targets for Antiretroviral Therapy
    Jacqueline D. Reeves
    Andrew J. Piefer
    Drugs, 2005, 65 : 1747 - 1766
  • [4] Emerging targets in cancer drug resistance
    Kumar, Shashank
    Kushwaha, Prem Prakash
    Gupta, Sanjay
    CANCER DRUG RESISTANCE, 2019, 2 (02) : 161 - 177
  • [5] Metallocarboxypeptidases: Emerging drug targets in biomedicine
    Arolas, Joan L.
    Vendrell, Josep
    Aviles, Francesc X.
    Fricker, Lloyd D.
    CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (04) : 349 - 366
  • [6] Emerging drug targets for pain treatment
    Li, Jun-Xu
    Zhang, Yanan
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2012, 681 (1-3) : 1 - 5
  • [7] Emerging migraine treatments and drug targets
    Olesen, Jes
    Ashina, Messoud
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2011, 32 (06) : 352 - 359
  • [8] Tuberculosis drug discovery and emerging targets
    Mdluli, Khisimuzi
    Kaneko, Takushi
    Upton, Anna
    ANTIMICROBIAL THERAPEUTICS REVIEWS: INFECTIOUS DISEASES OF CURRENT AND EMERGING CONCERN, 2014, 1323 : 56 - 75
  • [9] Emerging non CGRP drug targets
    Ashina, Messoud
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [10] Axial spondyloarthritis: emerging drug targets
    Cherqaoui, Bilade
    Araujo, Luiza M.
    Glatigny, Simon
    Breban, Maxime
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2021, 25 (08) : 633 - 644
12345